Last updated on May 2020

Long-term Antipsychotic Pediatric Safety Trial

Brief description of study

The purpose is to evaluate the long-term pathologic weight changes associated with multi-year risperidone or aripiprazole therapy in 3 - <18-year-old children, who have varying durations of prior antipsychotic drug exposure from the start of study Month 0 (M0). This is critical because children appear to have greater vulnerability to antipsychotic-associated weight gain than adults, and obesity has significant effects on morbidity and mortality.

Detailed Study Description

Prospective, multi-site, Phase 4, longitudinal observational study designed to systematically collect robust longitudinal post-marketing safety and quality of life data about multi-year pediatric treatment with risperidone or aripiprazole. Screening may occur for up to 37 days prior to enrollment. Assessments will occur at in-person visits planned at months 0, 6, 12, 18 and 24, and at unscheduled, in-person visits that study staff request when the participant switches or stops antipsychotic monotherapy with risperidone or aripiprazole, adds or stops treatment with a weight modifying agent, becomes pregnant, chooses to withdraw from the study prematurely or, has an ongoing Serious Adverse Event (SAE) that requires further assessment. Monthly remote interim contacts occurring between in-person visits will monitor for changes (other than dose related) in antipsychotic therapy or weight modifying treatments, potential SAEs, and potential pregnancy. The participant, his/her parent/guardian, and the participant's personal psychotropic- prescribing medical provider (PPPMP) will make any and all decisions related to antipsychotic medications; any other medications; and the participant's current mental state, developmental/psychiatric condition, and level of risk for potential harm to self or others independent of the study procedures and assessments. Study staff (SS) will share all lab results and changes in the participant's AEs or clinical presentation, which the study medical clinician (SMC) considers medically concerning based on the participant's assessment during in-person visits, with the participant's PPPMP. If an emergency safety concern is evident during an in-person visit, the SMC will immediately assess the participant, following medical standard-of- care procedures, to determine whether the participant is safe to leave the clinic or requires additional emergency care. If new or worsening symptoms are reported by the participant or parent/guardian during remote interim contacts, the participant and/or parent/guardian will be instructed to contact the PPPMP directly.

Clinical Study Identifier: NCT03522168

Find a site near you

Start Over

OM Research

Lancaster, CA United States
  Connect »

Beacon Medical Group

South Bend, IN United States
  Connect »

Baylor College of Medicine

Houston, TX United States
  Connect »

UCLA Semel Institute

Los Angeles, CA United States
  Connect »

AMR-Baber Research, Inc.

Naperville, IL United States
  Connect »

Kennedy Krieger Institute

Baltimore, MD United States
  Connect »

Neurobehavioral Medicine Group

Bloomfield Hills, MI United States
  Connect »

University of Virginia

Charlottesville, VA United States
  Connect »

IACT Health

Columbus, GA United States
  Connect »

University of Cincinnati

Cincinnati, OH United States
  Connect »

IACT Health

Grayson, GA United States
  Connect »

Yale Child Study Center

New Haven, CT United States
  Connect »

Clinical Trials Solution

Hialeah, FL United States
  Connect »

Cook Children's Medical Center

Fort Worth, TX United States
  Connect »

Neuropsychiatric Associates

Woodstock, VT United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.